These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34825292)

  • 1. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
    J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Verma A; Rafiq S
    Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Feldman L; Brown C; Badie B
    Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
    Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
    J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Jindal V
    Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
    Choi SI; Yin J
    Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 17. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight.
    Land CA; Musich PR; Haydar D; Krenciute G; Xie Q
    J Transl Med; 2020 Nov; 18(1):428. PubMed ID: 33176788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.